计算溶液所需的质量、体积或浓度。
为什么选择此级别
提供 ≥99% 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
避光,-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue with anti-inflammatory activity. Anti-inflammatory agent 35 blocks mitogen-activated protein kinase (MAPK) signaling and p65 nuclear translocation of NF-kB. Anti-inflammatory agent 35 also inhibits yellow neutrophil infiltration and pro-inflammatory cytokine production. Anti-inflammatory agent 35 significantly attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI) in vivo
In Vitro
Anti-inflammatory agent 35 (compound 5a27) (10 μM; 30 min) inhibits the production of proinflammatory cytokines (IL-6, TNF-α) induced by LPS (0.5 μg/mL; 24 h) without cytotoxicity in mouse primary macrophages (MPMs). Anti-inflammatory agent 35 inhibits the production of IL-6, TNF-α with IC50s of 2.23 μM and 2.40 μM, respectively. Anti-inflammatory agent 35 (10 μM; 30 min) significantly inhibits LPS-induced activation in RAW 264.7 mouse macrophages. And it markedly inhibits p-p38 and p-ERK, decreases IκB level, indicating the suppression of MAPK and NF-κB signaling. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: RAW 264.7 mouse macrophages Concentration: 10 μM Incubation Time: 30 min; followed by incubation with 0.5 μg/mL LPS for another 30 min Result: Decreased the phosphorylation of p38 and ERK. And down-regulated IκB (inhibitor of NF-κB), inhibits the transcription of TNF-α, IL-6, IL-1β, ICAM-1.
In Vivo
Anti-inflammatory agent 35 (compound 5a27) (50 mg/kg; po; single dose, monitored 0-25 min) has a better bioavailability than curcumin . Anti-inflammatory agent 35 (10 mg/kg; ip; once daily for 1 week) improves LPS-induced ALI by inhibiting inflammation in mice model . The pharmacokinetic parameters in rats Route Dose (mg/kg) AUC (0-t) (μg/L·h) AUC (0-∞) (μg/L·h) MRT (0-t) (h) MRT (0-∞) (h) t 1/2 (h) T max (h) CLz/F (L/h/kg) Vz/F (L/kg) C max p.o 50 231.2 325.6 7.8 12.3 6.7 3.3 5062.6 827.1 113.3 i.v 5 34.3 122.4 11.3 19.9 0.2 0.1 404.4 59.5 16.4 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: ALI mouse model (C57BL/6 mice) Dosage: 10 mg/kg Administration: Intraperitoneal injection, once daily for 1 week; 30 min later every dose, followed by 5 mg/kg LPS, intratracheal injection Result: Significantly normalized the wet/dry ratio of lungs.
Form:Solid
IC50& Target:p38 MAPK ERK I-kappaBalpha IL-6 p65 NF-κB
规格
别名
抗炎剂 35
规格或纯度
≥99%
英文名称
Anti-inflammatory agent 35
生化机理
抗炎剂 35（化合物 5a27）是一种口服活性姜黄素类似物，具有抗炎活性。抗炎剂 35 能阻断丝裂原活化蛋白激酶（MAPK）信号传导和 NF-kB 的 p65 核转位。抗炎
储存条件
避光,-80℃储存
运输条件
特低温运输
作用类型
抑制剂
纯度
≥99%
名称和识别符
分子类型
小分子
分子量
495.52
技术文档
高级数据
化学和物理性质
溶解性
DMSO : 16.67 mg/mL (33.64 mM; ultrasonic and warming and heat to 60°C)
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）